A5060320368- Breast Cancer Treatment Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- BRCA gene mutations in cancer
- Angiogenesis and VEGF in Cancer
- Estrogen and related hormone effects
- Cancer Genomics and Diagnostics
- Male Breast Health Studies
- Cancer Cells and Metastasis
- RNA modifications and cancer
- Cancer-related Molecular Pathways
- Lung Cancer Treatments and Mutations
- Bioinformatics and Genomic Networks
- Breast Lesions and Carcinomas
- Cancer, Lipids, and Metabolism
- Brain Metastases and Treatment
- PARP inhibition in cancer therapy
- Mechanisms of cancer metastasis
- Glutathione Transferases and Polymorphisms
- Inflammatory mediators and NSAID effects
- Chronic Lymphocytic Leukemia Research
- Cancer and Skin Lesions
- Patient-Provider Communication in Healthcare
- Lung Cancer Research Studies
University of Gothenburg
2015-2025
Sahlgrenska University Hospital
2014-2025
Karolinska Institutet
2008-2022
Landstinget i Kalmar län
2021
Cargotec (Poland)
2021
Institute of Clinical Research
2021
European Organisation for Research and Treatment of Cancer
2019
Cancer Trials Ireland
2018-2019
Breast International Group
2018-2019
Beatson West of Scotland Cancer Centre
2019
Poly(adenosine diphosphate–ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence patients BRCA1 or BRCA2 germline mutation–associated early breast cancer.
PURPOSE The prognostic value of vascular endothelial growth factor (VEGF) protein, known to stimulate and angiogenesis, was evaluated in node-negative breast carcinoma (NNBC) compared with established factors. PATIENTS AND METHODS In 525 consecutive patients primary invasive NNBC (T1-2N0M0; tumor, node, metastasis stage), whom 500 did not receive any systemic therapy, the cytosolic levels VEGF165 were measured by using a quantitative enzyme-linked immunosorbent assay. median follow-up 46...
PURPOSE: To determine the predictive value of vascular endothelial growth factor (VEGF) for relapse-free survival (RFS) and overall (OS) in primary node-positive breast cancer (NPBC) after adjuvant endocrine treatment or chemotherapy. MATERIALS AND METHODS: VEGF was quantitatively measured tumor cytosols from 362 consecutive patients with NPBC using an enzyme immunoassay human 165 . Adjuvant given to all patients, either as therapy (n = 250) chemotherapy 112). The median follow-up time 56...
Abstract Purpose To determine the biology, recurrence rate, metastatic patterns and survival times in primary triple-negative breast cancer (TNBC) with focus on comparison between younger elderly patients. Methods Patients TNBC stage I–IV diagnosed from 2007 to 2015 were identified information tumor stage, treatment, recurrences death recorded. Results A total of 524 patients, median age 60 years (range 24–94) a follow-up 55 months 0–129) identified. Stage was similar (< 40 years) ( n =...
BMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of or weight. This preplanned analysis the global randomized PALLAS trial investigates impact on side-effect profile, treatment adherence, efficacy palbociclib.
The angiogenic factor vascular endothelial growth (VEGF) predicts outcome in primary breast carcinoma. Alteration of the p53 gene causes down-regulation expression thrombospondin-1, a natural inhibitor angiogenesis. This study was conducted to investigate association between mutant protein and VEGF expression, prognostic value these factors. VEGF165 were measured tumour cytosols by enzyme immunoassays. Recurrence-free survival (RFS) overall (OS) estimated 833 consecutive patients, 485...
Clinical outcome of patients with triple-negative breast cancer (TNBC) is highly variable. This study aims to identify and validate a prognostic protein signature for TNBC reduce unnecessary adjuvant systemic therapy. Frozen primary tumors were collected from 126 lymph node–negative therapy–naive patients. These samples used global proteome profiling in two series: an in-house training (n = 63) multicenter test set. Patients who remained free distant metastasis minimum 5 years after surgery...
We and others have recently shown that tumor characteristics are altered throughout progression. These findings emphasize the need for re-examination of at relapse led to recommendations from ESMO Swedish Breast Cancer group. Here, we aim determine whether molecular subtypes in breast cancer metastases confer clinically relevant prognostic information patients.
Purpose To evaluate the benefit of low-dose cyclophosphamide and methotrexate (CM) maintenance, which previously demonstrated antitumor activity few adverse effects in advanced breast cancer, early cancer. Patients Methods International Breast Cancer Study Group (IBCSG) Trial 22-00, a randomized phase III clinical trial, enrolled 1,086 women (1,081 intent-to-treat) from November 2000 to December 2012. Women with estrogen receptor– progesterone receptor–negative (< 10% positive cells by...
Abstract Tamoxifen, a partial estrogen receptor antagonist, is part of the standard treatment both primary and advanced breast cancers. However, significant proportions cancers are either de novo resistant or develop tamoxifen resistance during course through mechanisms which have been only partly characterized. We previously found that high vascular endothelial growth factor (VEGF) VEGF 2 (VEGFR2) expression concomitant p38 mitogen-activated protein kinase activity within predict poor...
About one-third of oestrogen receptor alpha-positive breast cancer patients treated with tamoxifen relapse. Here we identify the nuclear retinoic acid alpha as a marker resistance. Using quantitative mass spectrometry-based proteomics, show that protein networks and levels differ in tamoxifen-sensitive (MCF7) tamoxifen-resistant (LCC2) cell line. High intratumoural also correlate reduced relapse-free survival adjuvant solely. A similar expression pattern is seen comparable independent...
Transcriptomic profiles have shown promise as predictors of response to neoadjuvant chemotherapy in breast cancer (BC). This study aimed explore their predictive value the advanced BC (ABC) setting.In a Phase 3 trial first-line ABC, fine needle aspiration biopsy (FNAB) was obtained at baseline. Intrinsic molecular subtypes and gene modules related immune response, proliferation, oestrogen receptor (ER) signalling recurring genetic alterations were analysed for association with objective...
The complete molecular basis of the organ-specificity metastasis is elusive. This study aimed to provide an independent characterization transcriptional landscape breast cancer metastases with specific objective identify liver metastasis-selective genes prognostic importance following primary tumor diagnosis.A cohort 304 women advanced was studied. Associations between site recurrence and clinicopathologic features were investigated. Fine-needle aspirates (n = 91) subjected whole-genome...
Cancer is a growing concern in Ethiopia. Though communication essential for the treatment process, few studies have looked at Ethiopian cancer care. Due to large number of patients and scarcity resources, it vital understand how manage consultations order effectively help as many possible this challenging work environment. Thus, research needed analyze communicative challenges experienced by physicians, patients, family caregivers, successfully handle patient care practice.We explore present...
Abstract Background: Metronomic chemotherapy (MCT) is an available treatment option in patients with metastatic breast cancer. Since patients' perspectives concerning selection may differ from those of the oncologists, increased knowledge on patient perspective needed to facilitate shared decision making. The aim was explore experiences metronomic capecitabine and cyclophosphamide (MCT-CX) focus perceived benefits drawbacks everyday life. Methods: This a qualitative descriptive study using...